Oraliva, Inc.
Durham, NC
- UEI
- LMZ2DG9M4RH6
- CAGE
- 8MSK5
- Primary NAICS
- 621512 Diagnostic Imaging Centers
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 2 Davis Dr, Durham, NC 27703, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Point of care diagnostic to improve access to gynecological screening in low-resource settings - oraliva and partners… | National Cancer Institute | $400,000 | |
| Sttr phase II: portable single cell cytology and predictive analysis platform for the early detection of epithelial… | National Science Foundation | $1,244,392 | |
| AI-linked cytomics-on-a-chip to enable near-real time identification and management of oral lichenoid lesions in primary… | National Institute of Dental and Craniofacial Research | $3,054,356 | |
| Sttr phase i: portable single cell cytology and predictive analysis platform for the early detection of epithelial… | National Science Foundation | $275,000 |
About Oraliva, Inc.
Oraliva, Inc. is a corporate technology entity based in Durham, North Carolina, focused on developing advanced diagnostic technologies leveraging artificial intelligence and microfluidics for early cancer detection. The company specializes in creating portable, programmable single-cell cytology platforms that enable near real-time identification and management of various epithelial cancer types through innovative point-of-care screening technologies. Their core technological approach combines microfluidic engineering with artificial intelligence to provide predictive analysis and accurate cellular diagnostics across multiple medical domains.
Through federal grant awards, Oraliva, Inc. has secured significant funding from agencies like the National Science Foundation, National Cancer Institute, and National Institute of Dental and Craniofacial Research to develop cutting-edge diagnostic platforms. Their primary research focuses on creating AI-linked cytomics-on-a-chip technologies for early detection of epithelial cancers, with specific applications in gynecological screening, oral cancer detection, and point-of-care diagnostic tools. The company has received multiple grants totaling approximately $3.1 million, including a $1,244,392 NSF Cooperative Agreement for developing a portable single-cell cytology platform, a $1,178,476 NIDCR grant for oral lesion detection, and a $400,000 NCI project grant for gynecological screening innovations. Oraliva has established collaborative partnerships with academic institutions like the University of Miami, University of North Carolina Chapel Hill, and New York University Langone, as well as industry partners such as Delta Dental, to expand the potential applications of their diagnostic technologies.
Quick answers
What is Oraliva, Inc.'s UEI?
Oraliva, Inc.'s Unique Entity ID (UEI) in SAM.gov is LMZ2DG9M4RH6.
What is Oraliva, Inc.'s CAGE code?
Oraliva, Inc.'s CAGE code is 8MSK5.
What is Oraliva, Inc.'s primary NAICS code?
Oraliva, Inc.'s primary NAICS code is 621512 (Diagnostic Imaging Centers).
Where is Oraliva, Inc. located?
Oraliva, Inc.'s physical address in SAM.gov is 2 Davis Dr, Durham, NC 27703, USA.
Is Oraliva, Inc. registered in SAM.gov?
Yes. Oraliva, Inc.'s SAM.gov registration is active through March 5, 2027.
What is Oraliva, Inc.'s most recent federal award?
Oraliva, Inc.'s most recent federal grant award is Point of care diagnostic to improve access to gynecological screening in low-resource settings - oraliva and partners… (R41CA298398), from National Cancer Institute, on September 1, 2025.
On GovTribe
See Oraliva, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors